This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
by Zacks Equity Research
Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -26.87% and 1.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Oct 7, 2019
by Zacks Equity Research
Companies in the news are: COST, BP, HPQ and SRPT
Why Is Sarepta Therapeutics (SRPT) Down 33.1% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Company News For Aug 21, 2019
by Zacks Equity Research
Companies in the news are: KSS, MDT, BIDU and SRPT
Sarepta Stock Falls as FDA Denies Approval to Golodirsen
by Zacks Equity Research
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
by Zacks Equity Research
Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.
Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Sarepta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -246.30% and 3.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Has Sarepta Therapeutics (SRPT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRPT) Outperforming Other Medical Stocks This Year?
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.
Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SRPT) Outperforming Other Medical Stocks This Year?
Sarepta Stock Up Almost 40% This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
by Zacks Equity Research
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.